Assenagon Asset Management S.A. Purchases 132,942 Shares of REGENXBIO Inc. $RGNX

Assenagon Asset Management S.A. increased its position in REGENXBIO Inc. (NASDAQ:RGNX) by 23.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 705,403 shares of the biotechnology company’s stock after purchasing an additional 132,942 shares during the quarter. Assenagon Asset Management S.A. owned approximately 1.40% of REGENXBIO worth $6,807,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Voss Capital LP grew its position in shares of REGENXBIO by 47.4% during the 2nd quarter. Voss Capital LP now owns 575,000 shares of the biotechnology company’s stock worth $4,721,000 after buying an additional 185,000 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of REGENXBIO during the first quarter worth $1,123,000. Squarepoint Ops LLC increased its holdings in REGENXBIO by 2,049.0% in the second quarter. Squarepoint Ops LLC now owns 219,288 shares of the biotechnology company’s stock valued at $1,800,000 after purchasing an additional 209,084 shares during the last quarter. Invesco Ltd. increased its holdings in REGENXBIO by 52.4% in the first quarter. Invesco Ltd. now owns 79,469 shares of the biotechnology company’s stock valued at $568,000 after purchasing an additional 27,341 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in REGENXBIO in the second quarter valued at about $1,453,000. 88.08% of the stock is owned by institutional investors.

REGENXBIO Price Performance

Shares of NASDAQ:RGNX opened at $14.59 on Monday. The company’s 50-day moving average price is $12.46 and its two-hundred day moving average price is $10.24. REGENXBIO Inc. has a one year low of $5.03 and a one year high of $15.20. The stock has a market capitalization of $738.55 million, a PE ratio of -4.20 and a beta of 1.14.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.18. REGENXBIO had a negative return on equity of 78.29% and a negative net margin of 110.29%.The business had revenue of $29.73 million for the quarter, compared to the consensus estimate of $24.41 million. On average, analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

Insider Activity at REGENXBIO

In other news, CEO Curran Simpson sold 20,811 shares of the stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $12.62, for a total value of $262,634.82. Following the completion of the sale, the chief executive officer owned 216,162 shares of the company’s stock, valued at approximately $2,727,964.44. This represents a 8.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 12.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on RGNX. HC Wainwright reiterated a “buy” rating and issued a $34.00 price target on shares of REGENXBIO in a research report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a research note on Wednesday, October 8th. Stifel Nicolaus raised their price target on REGENXBIO from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday. Chardan Capital reiterated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Thursday, November 20th. Finally, Leerink Partners lifted their price target on shares of REGENXBIO from $16.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $30.00.

REGENXBIO Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.